Foreword: Severe sepsis

American Journal of Surgery

Volumn 184, Issue 6 SUPPL. 1, 2002, Pages S3-S4

  Bernard, Gordon ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; DROTRECOGIN; ENDOTOXIN ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN C; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ANTIBODY;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; HUMAN; IMMUNITY; MEDICAL LITERATURE; MORTALITY; MULTIPLE ORGAN FAILURE; PATHOPHYSIOLOGY; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; RISK BENEFIT ANALYSIS; SEPSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0036942056     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(02)01131-5     Document Type: Editorial

References (22)

1. Matthay M.A. Severe sepsis - a new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med. 344:2001;759-762.
2. Wheeler A.P., Bernard G.R. Treating patients with severe sepsis. N Engl J Med. 340:1999;207-214.
3. Zeni F., Freeman B., Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock a reassessment . Crit Care Med. 25:1997;1095-1100.
4. Fuhrman B.P., Abraham E., Dellinger R.P. Futility of randomized, controlled ARDS trials - a new approach is needed. Crit Care Med. 27:1999;431-433.
5. Nasraway S.A. Jr. Sepsis research we must change course . Crit Care Med. 27:1999;427-430.
6. Rangel-Frausto M.S., Pittet D., Costigan M., et al. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA. 273:1995;117-123.
7. Chiron Announces Results of Phase III Study of Tifacogin in Severe Sepsis [Press Release]. Emeryville, CA: Chiron Corporation; November 21, 2001. Available at: http://www.chiron.com/investor/news/index.htm. Accessed November 1, 2002.
8. Corrigan J.J. Jr, Ray W.L., May N. Changes in the blood coagulation system associated with septicemia. N Engl J Med. 279:1968;851-856.
9. Hartman D.L., Bernard G.R., Helterbrand J.D., et al. Recombinant human activated protein C (rhAPC) improved coagulation abnormalities associated with severe sepsis. Intensive Care Med. 24:1998;S77.
10. Looney M.R., Matthay M.A. The role of protein C in sepsis. Curr Infect Dis Rep. 3:2001;413-418.
11. Smith D. Meeting report 13th Annual Congress of the European Society of Intensive Care Medicine, Rome, Italy . Crit Care. 4:2000;347-351.
12. Taylor F.B. Jr, Chang A., Esmon C.T., et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 79:1987;918-925.
13. Fisher C.J. Jr, Yan S.B. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med. 28:2000;S49-S56.
14. Yan S.B., Helterbrand J.D., Hartman D.L., et al. Low levels of protein C are associated with poor outcome in severe sepsis. Chest. 120:2001;915-922.
15. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 344:2001;699-709.
16. Joyce D.E., Gelbert L., Ciaccia A., et al. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem. 276:2001;11199-11203.
17. Esmon C.T. The protein C anticoagulant pathway. Arterioscler Thromb. 12:1992;135-145.
18. Papathanassoglou E.D., Moynihan J.A., Ackerman M.H. Does programmed cell death (apoptosis) play a role in the development of multiple organ dysfunction in critically ill patients? A review and a theoretical framework. Crit Care Med. 28:2000;537-549.
19. Bohme M.W., Deng Y., Rath U. Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils in vivo and in vitro studies . Immunology. 87:1996;134-140.
20. Faust S.N., Heyderman R.S., Levin M. Coagulation in severe sepsis a central role for thrombomodulin and activated protein C . Crit Care Med. 29:(7 suppl):2001;S62-S67.
21. Faust S.N., Levin M., Harrison O.B., et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med. 345:2001;408-416.
22. Yan S.B., Dhainaut J.F. Activated protein C versus protein C in severe sepsis. Crit Care Med. 29:(7 suppl):2001;S69-S74.